|
Re: RVX Board Thoughts Mar 18 2022 – Wishful Thinking
|
8
|
Resverlogix Corp.
|
Mar 19, 2022 04:29AM
|
|
Re: RVX ANNOUNCES TYPE C MEETING WITH FDA FOR CORAL, A PHASE 3 HIGH-RISK COVID-19 OUTPATIENT STUDY
|
2
|
Resverlogix Corp.
|
May 09, 2022 11:23AM
|
|
Re: RVX ANNOUNCES TYPE C MEETING WITH FDA FOR CORAL, A PHASE 3 HIGH-RISK COVID-19 OUTPATIENT STUDY
|
4
|
Resverlogix Corp.
|
May 09, 2022 12:13PM
|
|
Re: RVX AGM 12/22/2020 - rough transcript
|
8
|
Resverlogix Corp.
|
Dec 30, 2020 08:38PM
|
|
Re: RVX 208 and the cytokine storm syndrome
|
3
|
Resverlogix Corp.
|
Apr 20, 2020 12:20PM
|
|
Re: Rules of thumb and broken thumbs...
|
5
|
Resverlogix Corp.
|
Sep 29, 2020 06:12PM
|
|
Re: Round one
|
3
|
Resverlogix Corp.
|
Jan 27, 2022 01:05AM
|
|
Re: Round one
|
3
|
Resverlogix Corp.
|
Jan 27, 2022 11:14PM
|
|
Re: Rought Transcript: RVX Presentation at GCFF Virtual Conference – Investing In Innovation – 09/10/2020
|
8
|
Resverlogix Corp.
|
Sep 19, 2020 08:35PM
|
|
Re: Rough Transcript RVX 21_05_12_PBA_at_Noon...
|
4
|
Resverlogix Corp.
|
May 13, 2021 10:51PM
|
|
Re: Rough Transcript RVX 21_05_12_PBA_at_Noon...
|
2
|
Resverlogix Corp.
|
May 14, 2021 12:31PM
|
|
Re: Rough Transcript - 2021_06_22_AGM
|
7
|
Resverlogix Corp.
|
Jun 23, 2021 12:32AM
|
|
Re: Resverlogix warrants to be delisted June 21
|
9
|
Resverlogix Corp.
|
Jun 14, 2021 02:36PM
|
|
Re: Resverlogix Reschedules Update Webcast and Conference Call: Now February 4th 10AM MT
|
4
|
Resverlogix Corp.
|
Jan 27, 2021 06:20PM
|
|
Re: Resverlogix Announces Publication in High-impact Peer-reviewed Journal – Medicinal Research Reviews
|
6
|
Resverlogix Corp.
|
Sep 15, 2020 12:47PM
|
|
Re: Resverlogix Announces Private Placement
|
4
|
Resverlogix Corp.
|
Aug 14, 2020 08:01PM
|
|
Re: Resverlogix Announces One-Year Extension of Debenture
|
2
|
Resverlogix Corp.
|
Apr 19, 2022 09:50PM
|
|
Re: Resverlogix Announces New Research Findings Highlighting the Safety of BD2-selective BET Inhibitors
|
2
|
Resverlogix Corp.
|
Jun 08, 2022 01:32PM
|
|
Re: Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
|
3
|
Resverlogix Corp.
|
Sep 08, 2021 07:24PM
|
|
Re: Response from Sarah -were still a go
|
6
|
Resverlogix Corp.
|
Dec 02, 2021 06:38PM
|
